isomethyleugenol has been researched along with Carcinoma, Neuroendocrine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azzoni, C; Bordi, C; Bottarelli, L; Campanini, N; D'Adda, T; Pasquali, C; Pizzi, S; Rindi, G; Rossi, G | 1 |
| Bordi, C; Rindi, G | 1 |
1 review(s) available for isomethyleugenol and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics.
Topics: Carcinoma, Neuroendocrine; Cell Differentiation; Gastrointestinal Neoplasms; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Loss of Heterozygosity; Methylation; Pancreatic Neoplasms; Phenotype; Proto-Oncogene Proteins; Transforming Growth Factors; Tumor Suppressor Proteins | 2005 |
1 other study(ies) available for isomethyleugenol and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Appendiceal Neoplasms; Carcinoma, Neuroendocrine; Cyclin D1; Duodenal Neoplasms; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Ileal Neoplasms; Intestinal Neoplasms; Loss of Heterozygosity; Male; Methylation; Middle Aged; Pancreatic Neoplasms; Promoter Regions, Genetic; Rectal Neoplasms; Stomach Neoplasms; Tumor Suppressor Proteins | 2005 |